Introduction
============

Hip fractures can have catastrophic outcomes for older adults. ^([@b1-cgj-22-148])^ They lead to pain, loss of function, institutionalization, and even death.^([@b2-cgj-22-148],[@b3-cgj-22-148])^ With our aging population, hip fractures will continue to be a population health problem.

In Canada, there have been increased efforts to both prevent and improve the care and outcomes of patients with hip fractures.^([@b4-cgj-22-148],[@b5-cgj-22-148])^ In this setting, a thorough understanding of the risk factors for these fractures remains important.

The seasonality of health outcomes can provide insights about the etiology of disease, as well as help care professionals and policy makers anticipate and prepare for outcomes.^([@b6-cgj-22-148])^ Where seasonal trends in hip fractures have been described across geographic regions previously, peaks were observed in cooler months.^([@b7-cgj-22-148]--[@b9-cgj-22-148])^ Slippery surfaces due to freezing temperatures, and vitamin D deficiency due to lack of sunlight, have been proposed as contributors to these trends.^([@b7-cgj-22-148],[@b9-cgj-22-148]--[@b11-cgj-22-148])^ However, non-weather factors might also partly explain hip fracture trends. People might be more vulnerable to falls at different times of year due to underlying illness or comorbidities such as infections. Seasonal variation in fracture rates might also be driven by temporal differences in social or behavioural factors.^([@b6-cgj-22-148])^ Patients, for example, might avoid or be unable to receive health care during particular times of the year (e.g., the holidays),^([@b12-cgj-22-148])^ which could impact their susceptibility to health outcomes. Additionally, if people travel outside a region at different times of the year (i.e., seasonal migration from cold to warm climates),^([@b12-cgj-22-148])^ their fractures might not be ascertainable in research studies.

There has been no recent evaluation of monthly variation in hip fractures in older adults in Canada. In the current study we provide an updated assessment of fracture trends in those \>65 years in the province of Ontario. We hypothesized that hip fractures would be most common during the cooler months. To examine potential reasons for seasonal variation in hip fractures, we ascertained the demographic characteristics and comorbidity profiles of patients with fractures over the months. To determine whether social or behavioural factors might influence fracture trends, we also examined variations in health-care utilization including visits to health-care professionals, blood tests, and prescription medication dispensing.

METHODS
=======

Study Design and Setting
------------------------

We conducted a population-based study of adults age \>65 years in Ontario, Canada from January 1 2011 until December 31 2015. We divided our study period into one-month intervals.

Ontario is a northern region between the 42nd and 57th latitudes, with cold winters and subzero temperatures. We have over 13 million residents who have universal coverage for hospitalizations, physician visits, and diagnostic testing. ^([@b13-cgj-22-148])^ People aged ≥65 years have universal access to prescription medications. Information on their health-care utilization is maintained in databases held at ICES. Databases are linked using unique, encoded identifiers. We report our study using the RECORD recommendations ([Appendix A](#app1-cgj-22-148){ref-type="app"}).^([@b14-cgj-22-148])^

Our study was approved by the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Ontario) and was analyzed at ICES according to a pre-specified protocol. Participant consent was not necessary as ICES is a named entity under Ontario's Personal Health Information Protection Act, and is able to receive and use health information to examine the province's health-care system.

Patients
--------

We considered for inclusion all adults \>65 years with a hospitalization for a hip fracture over the study period (defined as at least one code for a hip fracture during an inpatient hospital stay). Our coding algorithm for hip fracture included diagnostic and medical billing codes,^([@b15-cgj-22-148])^ similar to one validated previously (positive predictive value 83%, sensitivity 99%) ^([@b16-cgj-22-148])^ ([Appendix B](#app2-cgj-22-148){ref-type="app"}).

Prior to each study interval, we excluded the records of those: 1) with a missing age, sex or an invalid identification number, 2) an extreme or invalid age (negative age or age \>105), 3) who died on or before the study interval, or 4) who were not permanent residents of Ontario (i.e., did not have an Ontario residential postal code at the time of hospitalization). If patients had more than one encounter for a hip fracture over the study interval (i.e., month), we included only their first hospitalization.

Data Sources
------------

We used the records of several databases as our data sources. A full description of each database is included in [Appendix C](#app3-cgj-22-148){ref-type="app"}. In brief, the Registered Persons Database of Ontario provided demographic information for people who had been issued an Ontario health card. We used the Yearly Ontario Intercensal and Postcensal Population Estimates and Projection database to determine population denominators (Ontario Ministry of Health and Long-Term Care: IntelliHEALTH Ontario). We used the Ontario Drug Benefit (ODB) and the Drug Identification Number (DIN) databases to ascertain prescription medications. Prescription records are accurately maintained within the ODB with an error rate \< 1%.^([@b17-cgj-22-148])^ We assessed baseline comorbidities using the Ontario Diabetes Database (ODD),^([@b18-cgj-22-148])^ the Ontario Chronic Obstructive Pulmonary Disease,^([@b19-cgj-22-148])^ Rheumatoid Arthritis,^([@b20-cgj-22-148])^ and Crohn's and Colitis Datasets.^([@b21-cgj-22-148])^ Home care visits were captured using the Home Care Database, and physician visits were ascertained using the ICES Physician Database. We used the Canadian Institute for Health Information's Discharge Abstract Database (CIHI-DAD) and the National Ambulatory Care Reporting System (NACRS) Database to collect diagnostic and procedural information captured during hospital admissions and emergency department visits, respectively. We additionally used the Ontario Health Insurance Plan (OHIP) Database to capture patient diagnoses and procedures.

Covariates and outcomes were ascertained by a patient's presence in a derived database (e.g., the ODD), or administrative codes ([Appendix D](#app4-cgj-22-148){ref-type="app"}). Administrative codes are entered into databases including the CIHI-DAD and NACRS by trained personnel, based upon diagnoses recorded in the medical record by the health-care team. We used International Classification of Diseases 10th Revision (ICD-10), the enhanced Canadian version of the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10 CA), Canadian Classification of Health Interventions (CCI, post-2002), and OHIP fee and diagnostic codes.

Outcomes
--------

Our primary outcome was monthly variation in hip fracture hospitalizations in those \>65 years. Because the risk of osteoporosis and hip fracture is highest in the oldest old (i.e., ≥80 years),^([@b22-cgj-22-148])^ we stratified trends by age group (i.e., 66--79, ≥80 years).

We performed several additional analyses. We noted monthly variation in the demographic characteristics, comorbidity profiles, and health-care utilization of patients with fractures between September 2012 and August 2013 (study midpoint). We also examined trends in prescription medication dispensing for statins, as statins are the most commonly prescribed medication to older adults in Canada.^([@b23-cgj-22-148])^ Finally, to evaluate if seasonality in hip fractures might be due to older adults leaving our region over particular months of the year (i.e., 'snowbirding'),^([@b24-cgj-22-148])^ we examined monthly variation in travel supplies for statins (i.e., a prescription dispensed for \>100 tablets), over the study period.^([@b25-cgj-22-148])^

Statistical Analysis
--------------------

Numerators were the number of patients with at least one hospital encounter with a hip fracture over the study period, stratified by age. Denominators for all months were the estimated population of Ontario on July 1st of the relevant year in the age strata. To consider population changes over time, we calculated monthly encounter rates and their associated 95% confidence intervals (CI).

Based upon prior methods,^([@b6-cgj-22-148])^ we used time series analyses to assess for seasonality in hip fractures, as well as the strength of the relationship. We first visualized the raw data and then fitted regression lines to detect trends. We then used differencing methods to ensure data stationarity. Next, we used spectral analyses to detect statistically significant seasonality, the Fisher Kappa Test to determine if there was a major sinusoidal component, and the Bartlett Kolmogorov Smirnov Test to examine departures from the null hypothesis of pure white noise. We also examined spectral plots of the data (i.e., spectral density vs. data frequency) to identify the cyclic structure of the series, and we conducted multitaper spectral analyses. To examine the strength of the seasonal relationships, we generated R^2^ autoregression coefficients, which are the coefficients of determination of the autoregressive regression models fitted to the data. Coefficients of 0 to \< 0.4 represent weak seasonality, 0.4 to \< 0.7 moderate to strong, and 0.7 to 1 very strong to perfect seasonality.^([@b6-cgj-22-148],[@b26-cgj-22-148])^

We used descriptive statistics to summarize the characteristics, comorbidities, and health-care patterns of patients with a hip fracture from September 2012 until August 2013. If they had more than one encounter that year, we ascertained characteristics at the time of their first encounter only. We used Chi-squared analyses, one-way ANOVA, and Kruskal-Wallis tests to examine differences in covariates across the calendar months. For our prescription dispensing analysis, numerators were the number of patients 66--79 and ≥80 years with at least one statin prescription during the study interval, and denominators were the estimated population on July 1st of the relevant year in the age strata. We calculated monthly prescription rates and their associated 95% CIs. To evaluate for the possibility of snowbirding, we examined the maximum day supply of a statin per patient each month, and determined the number with a day supply of statins \>100 days. The denominator for this analysis was the total number of people who filled a statin prescription within the calendar year, across the two age groups. All analyses were conducted in SAS version 9.4 (SAS Institute, Inc., Cary, NC).

RESULTS
=======

Prior to each study interval, we excluded 12--51 (0.5--2.2%) records based upon an invalid identification number or sex, 141--220 (5.8--9.5%) records that had an invalid age, \<6 records with a death recorded on or before the study interval, and \<6 records for those who were not permanent residents of Ontario.

We included a total of 47,971 and 52,088 hip fracture hospitalizations in those 66--79 and ≥80 years between 2011--2015 in Ontario, Canada (42,694 and 47,648 unique patients, respectively).

Variation in Hip Fractures
--------------------------

Hip fracture rates appeared stable over time across groups. Strong seasonality was apparent in both age groups ([Table 1](#t1-cgj-22-148){ref-type="table"}). Fractures peaked in October and December, with a smaller peak in May. In those ≥80 years, fractures fell to a minimum in February. Fracture rates appeared to drop to a minimum in August in those 66--79 ([Figure 1](#f1-cgj-22-148){ref-type="fig"}).

Seasonal Characteristics of Fracture Patients
---------------------------------------------

The monthly characteristics of patients with hip fractures are presented in [Tables 2](#t2-cgj-22-148){ref-type="table"} and [3](#t3-cgj-22-148){ref-type="table"}. Compared with those who fractured during other months, patients with an autumn and winter fracture were more likely to have experienced a fall or fracture in the year prior. Those who were 66--79 years also appeared to have more comorbidities (i.e., higher Charlson comorbidity index), and used more unique medications than those who fractured at other times of the year.

Health-care Utilization
-----------------------

The health-care utilization of patients varied monthly. Primary care visits appeared less frequent across groups in the late winter and, in the oldest old, blood tests and specialist visits also appeared slightly less frequent ([Tables 2](#t2-cgj-22-148){ref-type="table"} and [3](#t3-cgj-22-148){ref-type="table"}). Statin prescription rates declined across both age groups in the late winter ([Figure 2](#f2-cgj-22-148){ref-type="fig"}). Both groups showed evidence of snowbirding over the winter months (i.e., higher rate of travel prescription fills in the late fall), but this appeared more common in those 66--79 years than in the oldest old ([Figure 3](#f3-cgj-22-148){ref-type="fig"}).

DISCUSSION
==========

Main Findings
-------------

In older adults in Ontario, hip fractures are most common in the late autumn, early winter, and spring. In the oldest old, hip fracture rates appeared lowest in the late winter.

As previously suggested, environmental factors might contribute to these trends. With exposure to ice and snow in the early winter (perhaps more so during the holidays),^([@b8-cgj-22-148],[@b27-cgj-22-148],[@b28-cgj-22-148])^ older people might be predisposed to slips and falls. A systematic review of studies that examined the association between hip fractures and at least one weather variable across 18 locations found that snow and ice were positively correlated with hip fractures at all latitudes.^([@b7-cgj-22-148])^ As hip fractures also peak in regions with no ice or snow,^([@b29-cgj-22-148],[@b30-cgj-22-148])^ colder temperatures (especially the acute lowering of temperature) might also contribute to monthly variation. When exposed to the cold, people might experience hypothermia and poor coordination. They might also dress in layers which could lead to trips and falls.^([@b7-cgj-22-148])^ An acute drop in temperature from a warmer summer to a cooler autumn might have contributed to the fracture peak we saw in October, especially if people had not yet adapted to the temperature change.^([@b31-cgj-22-148])^

Vitamin D deficiency could have also contributed to fracture trends.^([@b8-cgj-22-148],[@b10-cgj-22-148],[@b11-cgj-22-148],[@b32-cgj-22-148])^ Vitamin D is typically lowest at the end of the winter when parathyroid hormone is high.^([@b10-cgj-22-148])^ During winter months, bone turnover also increases and bone density declines.^([@b11-cgj-22-148],[@b33-cgj-22-148])^ These changes might have predisposed individuals to fracture. Vitamin D deficiency can also impair muscle strength and coordination.^([@b34-cgj-22-148])^ A darker winter might have also impaired visual acuity.^([@b35-cgj-22-148])^

Beyond environmental influences, we found evidence that patient characteristics, comorbidities, and social/behavioural factors might contribute to hip fracture trends in older adults. Older adults who had a fracture appeared to be in poorer health in the autumn and winter. During these seasons, infections are more common,^([@b6-cgj-22-148])^ and patients might have been predisposed to falls and fracture while they were ill.

Respiratory illnesses peak in the spring in the older age groups,^([@b36-cgj-22-148])^ when we noted a second peak in fracture rates. This peak might have also been due to people becoming active again outside. In our study, people who had a hip fracture in the spring appeared healthier than those who fractured at other times of the year. Previous studies have noted that healthy active people are at higher risk of outdoor falls while engaging in vigorous activities.^([@b37-cgj-22-148],[@b38-cgj-22-148])^

Of particular interest, we observed that in the oldest old, fractures appeared less common in the late winter. During the late winter it is coldest in Canada^([@b39-cgj-22-148])^ and older adults might simply avoid the outdoors, especially if they have comorbidities, are immobilized, or institutionalized.^([@b9-cgj-22-148],[@b40-cgj-22-148],[@b41-cgj-22-148])^ Aligned with this, their health care utilization also appeared to decline with fewer primary care visits and a lower rate of prescription medication dispensing. Although there was evidence of snowbirding in both age groups, the trend seemed most apparent in those 66--79 years. This trend wouldn't sufficiently explain the decline in health-care utilization in the oldest old, suggesting that older seniors might avoid going outside during the late winter.

Comparison with Previous Literature
-----------------------------------

Hip fractures have been described to peak in the autumn and winter in older Canadian studies from Montreal.^([@b9-cgj-22-148],[@b27-cgj-22-148])^ Outside of Canada, in a Spanish study of people \>45 years (mean age 80 years), there was also an increased risk of fracture during these months.^([@b29-cgj-22-148])^ Similar trends have been described in Taiwan,^([@b8-cgj-22-148])^ as well as across the United States,^([@b42-cgj-22-148])^ Israel,^([@b28-cgj-22-148])^ Scotland, Hong Kong, New Zealand,^([@b30-cgj-22-148])^ and Norway.^([@b43-cgj-22-148])^

The decline in fractures in those ≥80 in the late winter has not been thoroughly described. While most studies note a trough in fracture rates over the summer months,^([@b41-cgj-22-148],[@b44-cgj-22-148])^ our extreme winter climate where temperatures can drop below −30°C in areas, might partly explain our findings.

Strengths and Weaknesses
------------------------

There are several strengths to the current study. It is a large, up-to-date, population-based study of 100,059 hip fracture encounters (89,913 unique individuals) in our province over a five-year period. Rather than simply describing fracture variation, we evaluated trends within two age strata, and examined variation in patient comorbidities and health services utilization.

There are some limitations to discuss. We could not exclude high-velocity fractures (i.e., from motor vehicle collisions) or pathological hip fractures, although it is estimated that over 95% of hip fractures are due to a fall.^([@b45-cgj-22-148])^ We also included procedural codes for hip fractures, and thus, double counting of encounters could have occurred. However, we minimized this risk by limiting to one hip fracture encounter per month. We used administrative data to ascertain our outcomes and this data were not specifically created to address our research question. However, our data can minimize the bias associated with self-report and surveys.^([@b16-cgj-22-148])^ Changes in coding definitions might have occurred over the study period and may have affected our temporal trend analyses. We also could not determine the location of the hip fractures (i.e., indoors vs. outdoors). Our study population also included a mix of both community and long-term care residents.

Due to the size and duration of our study, we were only able to ascertain the characteristics and comorbidities of patients over one year. We were unable to evaluate factors, including frailty and balance, which can impact fracture risk. Importantly, this was an ecological study and we cannot infer causation at an individual level. Our results are only fully generalizable to those living in Ontario.

Implications
------------

Our study has implications for practice, policy, and research. First, given the possible link between hip fractures and environmental factors, patients should be advised to be cautious while traversing snow and ice, and to wear proper footwear. ^([@b46-cgj-22-148])^ Even if indoors during the cooler months, they might be warned of tripping hazards, especially when layering for the colder weather. When people are in poorer health, they might be cautioned about the risk of falls. Further, physicians might replace vitamin D and ensure adequate calcium intake during the winter months, especially in the frail and institutionalized. ^([@b34-cgj-22-148],[@b47-cgj-22-148],[@b48-cgj-22-148])^ A role for UV light exposure in the winter has also been suggested.^([@b8-cgj-22-148])^

From a policy standpoint, health administrators might plan resources accordingly. Operating times for hip fractures might be opened in the cooler seasons, and hospitals might be prepared for more consultations. Awareness of fracture peaks might promote timely assessments and treatment.^([@b4-cgj-22-148])^ Troughs in fracture rates and health services utilization over the winter might raise the possibility of social isolation; as a result, ensuring that home-based resources are available might be of importance (e.g., home care services, exercise programs, food delivery). This might be especially needed by those who are too frail to leave their residence.^([@b35-cgj-22-148])^ For city workers and planners, timely ice and snow removal also remains important.^([@b35-cgj-22-148])^

Finally, from a research perspective, researchers might better consider snowbirding when conducting trend analyses, to ensure accurate denominators.

CONCLUSIONS
===========

In our region, the oldest old have a unique pattern of hip fracture hospitalizations across the months. Beyond environmental influences, complex patient, social, and behavioural factors might contribute to observed trends.
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  ---------------------------------------------------------------------------
  *Variable*     *Database*   *Codes*
  -------------- ------------ -----------------------------------------------
  Hip fracture   CIHI-DAD     ICD 10/ICD 10-CA: S720, S721\
                              CCI: 1VA73, 1VC73, 1VA74, 1VA53, 1VC74, 1VA80

  ---------------------------------------------------------------------------

CIHI-DAD = Canadian Institute for Health Information's-Discharge Abstract Database; CCI = Canadian Classification of Health Interventions; ICD-10/ICD 10-CA = International Classification of Diseases 10^th^ Revision/Enhanced Canadian version of the 10^th^ Revision of the International Statistical Classification of Diseases and Health Related Problems.

  *Database*                                                                               *Details*
  ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Registered Persons Database of Ontario                                                   Contains vital statistics for all residents who have been issued an Ontario health card.
  Yearly Ontario Intercensal and Postcensal Population Estimates and Projection Database   Contains Ontario population estimates by sex, age and geographic areas.
  Ontario Drug Benefits Database                                                           Contains prescription medication for adults ≥65 years and those using social assistance.
  Drug Identification Number Database                                                      Contains Drug Identification Numbers used in Canada from 1990.
  Ontario Diabetes Database                                                                Contains all patients with diabetes identified since 1991 (based upon hospitalization codes and physician diagnoses).
  Ontario Chronic Obstructive Pulmonary Disease Database                                   Contains all patients with COPD identified since 1991 (based upon hospitalization codes, physician services claims).
  Ontario Rheumatoid Arthritis Database                                                    Contains all patients with rheumatoid arthritis identified since 1991 (based upon hospitalization codes, physician services claims).
  Ontario Crohn's and Colitis Cohort Database                                              Includes all Ontarians with Crohn's or colitis identified since 1991 (defined by hospitalization codes, prescription medications, and physicians' services claims).
  Home Care Database                                                                       Contains information about home care services acquired from the Ontario Association of Community Care Access Centres.
  ICES Physicians Database                                                                 Contains information about all physicians in Ontario (ascertained from the Ontario Health Insurance Plan and the Ontario Physician Human Resource Data Centre).
  Canadian Institute for Health Information's Discharge Abstract Database                  Contains diagnostic and procedural information coded during inpatient hospitalizations.
  National Ambulatory Care Reporting System Database                                       Contains diagnostic and procedural information coded during emergency room encounters.
  Ontario Health Insurance Plan Database                                                   Contains physician diagnostic and billing codes.

![](cgj-22-148t7a)

  *Variable*                              *Database*   *Codes/Notes*
  --------------------------------------- ------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Comorbidities*                                      
  Acute kidney injury                     CIHI-DAD     ICD 10/ICD 10-CA: N17
  Acute myocardial infarction             CIHI-DAD     ICD10/ICD 10-CA: I21, I22
                                          NACRS        
  Alcoholism                              CIHI-DAD     ICD 10/ICD 10-CA: E244, E512, F10, G312, G621, G721, I426, K292, K70, K860, T510, X45, X65, Y15, Y573, Z502, Z714, Z721, T519
  Chronic kidney disease                  CIHI-DAD     ICD 10/ICD10-CA: E102, E112, E132, E142, I12, I13, N08, N18, N19
                                          OHIP         OHIP DX: 403, 585
  Chronic liver disease                   CIHI-DAD     ICD 10/ICD 10-CA: B16, B17, B18, B19, I85, R17, R18, R160, R162, B942, Z225, E831, E830, K70, K713, K714, K715, K717, K721, K729, K73, K74, K753, K754, K758, K759, K76, K77
                                          OHIP         
                                                       OHIP DX: 571, 573, 070
                                                       OHIP Fee: Z551, Z554
  Chronic obstructive pulmonary disease   COPD         In COPD database
  Crohn's or colitis                      OCCD         In OCCD database
  Dementia                                CIHI-DAD     ICD 10/ICD 10-CA: F065, F066, F068, F069, F09, F00, F01, F02, F03, F051, G30, G31, R54
                                          OHIP         
                                                       OHIP DX: 290, 331, 797
  Diabetes                                ODD          In ODD database
  Fall                                    CIHI-DAD     ICD 10/ICD 10-CA: W00-W19
                                          NACRS        
                                          OHIP         
  Fracture                                CIHI-DAD     Hip
                                          NACRS        ICD10/ICD 10-CA: S720, S721
                                          OHIP         CCI: 1VA73, 1VC73, 1VA74, 1VA53, 1VC74, 1VA80
                                                       Forearm
                                                       ICD10/ICD 10-CA: S52
                                                       CCI: 1TV73, 1TV74, 1TV03
                                                       OHIP FEE: F014, F022, F023, F025, F026, F028, F030, F032, F033, F046, F024, F027, F031, Z203
                                                       Humerus
                                                       ICD10/ICD 10-C: S422
                                                       Pelvis
                                                       ICD10/ICD 10-CA: S321, S322, S324, S323, S325, S327, S328
  Major cancer                            CIHI-DAD     ICD10/ICD 10-CA: 971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56, C61, C82, C83, C85, C91, C92, C93, C94, C95, D00, D05, D010, D011, D012, D022, D075
                                          OHIP         
                                                       OHIP DX: 203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 174, 175, 183, 185
  Seizure                                 CIHI-DAD     ICD 10/ICD 10-CA: G40, G41, R560, R568
  Sepsis                                  CIHI-DAD     ICD 10/ICD 10-CA: A021, A392, A393, A394, A400, A401, A402, A408, A409, A410, A411, A412, A403, A414, A4159, A413, A4150, A4151, A4152, A4158, A4180, A4188, A427, A419
  Rhabdomyolysis                          CIHI-DAD     ICD 10/ICD 10-CA: M628, T296, G210
  Rheumatoid arthritis                    ORAD         In ORAD database
  Medications                             ODB          
                                          DIN          
  *Health Care Utilization*                            
  General practitioner visit              IPDB         Evidence of at least 1 GP visit
  Any blood test                          OHIP         At least one OHIP lab test
  Specialist visit                        IPDB         Evidence of at least one specialist visit
  Home care visit                         HCD          Evidence of at least one home care visit

CIHI-DAD = Canadian Institute for Health Information's-Discharge Abstract Database; CCI = Canadian Classification of Health Interventions; COPD = Chronic Obstructive Pulmonary Disease Dataset; ICD 10/ICD 10-CA = International Classification of Diseases 10^th^ Revision/Enhanced Canadian version of the 10^th^ Revision of the International Statistical Classification of Diseases and Health Related Problems; OCCD = Ontario Crohn's and Colitis Dataset; OHIP DX = Ontario Health Insurance Plan Diagnostic; OHIP Fee = Ontario Health Insurance Plan Fee; ORAD = Ontario Rheumatoid Arthritis Dataset; RPDB = Registered Persons Database of Ontario.

![Rates of hip fracture encounters in patients 66--79 and ≥80 years in Ontario from 2011--2015](cgj-22-148f1){#f1-cgj-22-148}

![Statin prescription rates per 100 people aged 66--79 and ≥80 in Ontario](cgj-22-148f2){#f2-cgj-22-148}

![Rate of statin prescriptions with greater than 100 days supply per 10,000 people in Ontario, categorized by age groups, 66--79 and ≥80 years](cgj-22-148f3){#f3-cgj-22-148}

###### 

Statistical summary of seasonality of hip fracture encounters

  *Age Group*   *Fisher Kappa*   *BKS (p-value)*   *Autoregression r^2^Ccoefficient*[a](#tfn1-cgj-22-148){ref-type="table-fn"}   *Cycles (months)*
  ------------- ---------------- ----------------- ----------------------------------------------------------------------------- -------------------
  66--79        5.714            0.2791 (0.022)    0.625                                                                         6, 4
  ≥80           4.460            0.2799 (0.021)    0.645                                                                         6, 3, 12
  All ages      5.317            0.2965 (0.012)    0.725                                                                         6, 4, 3

An r^2^ coefficient of 0 to \< 0.4 represents weak seasonality, 0.4 to \< 0.7 moderate to strong seasonality, and 0.7 to 1 very strong to perfect seasonality.

BKS = Barlett Kolmogorov Smirnov

###### 

Characteristics of patients aged 66--79 with hip fractures from September 2012 to August 2013 (N=9014)

![](cgj-22-148t2a)

                                                                                      *Sep*        *Oct*        *Nov*        *Dec*        *Jan*        *Feb*         *Mar*         *Apr*        *May*          *Jun*        *Jul*        *Aug*        *P-value*[e](#tfn8-cgj-22-148){ref-type="table-fn"}
  ----------------------------------------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------- ------------- ------------ -------------- ------------ ------------ ------------ -----------------------------------------------------
  Age (mean ± SD)                                                                     72.7 ± 4.0   72.5 ± 4.1   72.6 ± 4.0   73.1 ± 4.0   72.8 ± 4.2   72.7 ± 3.93   72.63 ± 4.0   72.7 ± 4.1   72.80 ± 4.09   72.8 ± 4.1   72.7 ± 4.0   72.8 ± 4.2   0.513
  Female                                                                              467 (60.3)   503 (61.2)   462 (59.4)   393 (61.0)   478 (61.8)   439 (60.8)    471 (62.9)    517 (61.1)   511 (62.7)     450 (63.2)   447 (61.7)   410 (62.7)   0.949
  *Income Quintile*                                                                                                                                                                                                                                   
   1 (lowest)                                                                         129 (16.7)   150 (18.2)   131 (16.8)   136 (21.1)   149 (19.3)   151 (20.9)    131 (17.5)    161 (19.0)   130 (16.0)     130 (18.3)   125 (17.3)   98 (15.0)    0.452
   2                                                                                  152 (19.6)   162 (19.7)   154 (19.8)   120 (18.6)   160 (20.7)   145 (20.1)    156 (20.8)    152 (18.0)   159 (19.5)     148 (20.8)   150 (20.7)   130 (19.9)   
   3 or missing                                                                       161 (20.8)   177 (21.5)   165 (21.2)   135 (21.0)   152 (19.6)   131 (18.1)    161 (21.5)    174 (20.6)   161 (19.8)     119 (16.7)   141 (19.5)   129 (19.7)   
   4                                                                                  155 (20.0)   154 (18.7)   160 (20.6)   120 (18.6)   134 (17.3)   149 (20.6)    138 (18.4)    156 (18.4)   184 (22.6)     151 (21.2)   156 (21.5)   131 (20.0)   
   5 (highest)                                                                        177 (22.9)   179 (21.8)   168 (21.6)   133 (20.7)   179 (23.1)   146 (20.2)    163 (21.8)    203 (24.0)   181 (22.2)     164 (23.0)   152 (21.0)   166 (25.4)   
  *Residence*                                                                                                                                                                                                                                         
   Long-term care                                                                     32 (4.1)     23 (2.8)     26 (3.3)     30 (4.7)     27 (3.5)     19 (2.6)      20 (2.7)      22 (2.6)     30 (3.7)       22 (3.1)     30 (4.1)     33 (5.0)     
   Missing                                                                            16 (2.1)     23 (2.8)     19 (2.4)     30 (4.7)     10 (1.3)     23 (3.2)      19 (2.5)      27 (3.2)     24 (2.9)       17 (2.4)     24 (3.3)     19 (2.9)     
  *Discharge disposition*                                                                                                                                                                                                                             
   Acute care institution                                                             56 (7.2)     39 (4.7)     26 (3.3)     45 (7.0)     49 (6.3)     35 (4.8)      52 (6.9)      34 (4.0)     49 (6.0)       43 (6.0)     40 (5.5)     43 (6.6)     \<0.001
   Home without support                                                               183 (23.6)   235 (28.6)   204 (26.2)   130 (20.2)   179 (23.1)   189 (26.2)    177 (23.6)    153 (18.1)   188 (23.1)     149 (20.9)   154 (21.3)   148 (22.6)   
   Home with support                                                                  299 (38.6)   325 (39.5)   328 (42.2)   254 (39.4)   330 (42.6)   299 (41.4)    319 (42.6)    409 (48.3)   349 (42.8)     309 (43.4)   297 (41.0)   269 (41.1)   
   Long-term care                                                                     91 (11.8)    67 (8.2)     60 (7.7)     62 (9.6)     68 (8.8)     63 (8.7)      66 (8.8)      75 (8.9)     74 (9.1)       77 (10.8)    86 (11.9)    69 (10.6)    
   Rebab or other ambulatory facility or missing                                      145 (18.7)   156 (19.0)   160 (20.6)   153 (23.8)   148 (19.1)   136 (18.8)    135 (18.0)    175 (20.7)   155 (19.0)     134 (18.8)   147 (20.3)   125 (19.1)   
  *Comorbidities*[a](#tfn4-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                                           
   Fall in the 1 yr. prior                                                            43 (5.6)     34 (4.1)     21 (2.7)     30 (4.7)     34 (4.4)     31 (4.3)      24 (3.2)      23 (2.7)     13 (1.6)       20 (2.8)     23 (3.2)     18 (2.8)     0.001
   Fracture in the 1 yr. prior                                                        81 (10.5)    74 (9.0)     52 (6.7)     42 (6.5)     45 (5.8)     53 (7.3)      46 (6.1)      40 (4.7)     31 (3.8)       28 (3.9)     30 (4.1)     18 (2.8)     \<0.001
   Chronic liver disease                                                              29 (3.7)     30 (3.6)     35 (4.5)     34 (5.3)     42 (5.4)     37 (5.1)      31 (4.1)      42 (5.0)     35 (4.3)       34 (4.8)     32 (4.4)     28 (4.3)     0.847
   Dementia                                                                           95 (12.3)    91 (11.1)    92 (11.8)    83 (12.9)    98 (12.7)    87 (12.0)     91 (12.1)     93 (11.0)    86 (10.6)      83 (11.7)    72 (9.9)     92 (14.1)    0.585
   CKD                                                                                76 (9.8)     68 (8.3)     63 (8.1)     58 (9.0)     79 (10.2)    65 (9.0)      63 (8.4)      63 (7.4)     57 (7.0)       58 (8.1)     69 (9.5)     62 (9.5)     0.503
   RA                                                                                 35 (4.5)     48 (5.8)     30 (3.9)     29 (4.5)     28 (3.6)     37 (5.1)      35 (4.7)      33 (3.9)     29 (3.6)       31 (4.4)     35 (4.8)     30 (4.6)     0.626
   COPD                                                                               209 (27.0)   221 (26.9)   207 (26.6)   184 (28.6)   210 (27.1)   199 (27.6)    198 (26.4)    193 (22.8)   213 (26.1)     195 (27.4)   175 (24.2)   181 (27.7)   0.452
   IBD                                                                                10 (1.3)     ≤5           6 (0.8)      6 (0.9)      ≤5           8 (1.1)       13 (1.7)      10 (1.2)     8 (1.0)        7 (1.0)      7 (1.0)      8 (1.2)      0.728
   Diabetes                                                                           219 (28.3)   236 (28.7)   222 (28.5)   203 (31.5)   224 (28.9)   235 (32.5)    217 (29.0)    255 (30.1)   212 (26.0)     214 (30.1)   198 (27.3)   181 (27.7)   0.315
   Major cancer                                                                       132 (17.1)   126 (15.3)   129 (16.6)   101 (15.7)   106 (13.7)   119 (16.5)    115 (15.4)    129 (15.2)   121 (14.8)     115 (16.2)   106 (14.6)   102 (15.6)   0.902
   Alcoholism                                                                         28 (3.6)     21 (2.6)     23 (3.0)     22 (3.4)     22 (2.8)     23 (3.2)      24 (3.2)      26 (3.1)     17 (2.1)       27 (3.8)     21 (2.9)     24 (3.7)     0.819
   Seizure                                                                            16 (2.1)     12 (1.5)     14 (1.8)     8 (1.2)      12 (1.6)     9 (1.2)       10 (1.3)      19 (2.2)     ≤5             11 (1.5)     9 (1.2)      16 (2.4)     0.238
  *Other Conditions at Time of Encounter*[b](#tfn5-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                   
   Acute kidney injury                                                                11 (1.4)     12 (1.5)     11 (1.4)     14 (2.2)     12 (1.6%     11 (1.5)      ≤5            13 (1.5)     9 (1.1)        16 (2.2)     13 (1.8)     14 (2.1)     0.469
   Sepsis                                                                             ≤5           7 (0.9)      ≤5           ≤5           ≤5           ≤5            ≤5            6 (0.7)      ≤5             ≤5           ≤5           ≤5           0.347
   Rhabdomyolysis                                                                     ≤5           ≤5           ≤5           ≤5           ≤5           ≤5            ≤5            7 (0.8)      ≤5             ≤5           ≤5           6 (0.9)      0.655
   AMI                                                                                11 (1.4)     12 (1.5)     12 (1.5)     10 (1.6)     8 (1.0)      10 (1.4)      11 (1.5)      9 (1.1)      10 (1.2)       9 (1.3)      11 (1.5)     ≤5           0.978
  *Charlson Comorbidity Index*                                                                                                                                                                                                                        
   Mean ± SD                                                                          1.2 ± 1.9    1.1 ± 1.9    1.0 ± 1.7    1.3 ± 1.8    1.0 ± 1.6    1.2 ± 1.8     1.10 ± 1.82   1.0 ± 1.8    0.9 ± 1.6      1.1 ± 1.7    1.0 ± 1.8    1.00± 1.7    0.009
   Median (IQR)                                                                       0 (0--2)     0 (0--2)     0 (0--1)     1 (0--2)     0 (0--1)     0 (0--2)      0 (0--1)      0 (0--1)     0 (0--1)       0 (0--1)     0 (0--1)     0 (0--1)     \<0.001
   0 (no hospitalization)                                                             428 (55.3)   467 (56.8)   457 (58.7)   317 (49.2)   434 (56.1)   378 (52.4)    407 (54.3)    490 (57.9)   487 (59.8)     393 (55.2)   441 (60.9)   386 (59.0)   0.006
   1                                                                                  132 (17.1)   147 (17.9)   150 (19.3)   135 (21.0)   153 (19.8)   151 (20.9)    165 (22.0)    155 (18.3)   156 (19.1)     144 (20.2)   121 (16.7)   109 (16.7)   
   2                                                                                  80 (10.3)    86 (10.5)    71 (9.1)     81 (12.6)    90 (11.6)    81 (11.2)     76 (10.1)     85 (10.0)    76 (9.3)       69 (9.7)     66 (9.1)     77 (11.8)    
   3+                                                                                 134 (17.3)   122 (14.8)   100 (12.9)   111 (17.2)   97 (12.5)    112 (15.5)    101 (13.5)    116 (13.7)   96 (11.8)      106 (14.9)   96 (13.3)    82 (12.5)    
  *Medications*[c](#tfn6-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                                             
   Statins                                                                            332 (42.9)   352 (42.8)   365 (46.9)   277 (43.0)   348 (45.0)   328 (45.4)    339 (45.3)    376 (44.4)   355 (43.6)     299 (42.0)   318 (43.9)   282 (43.1)   0.827
   Bisphosphonate (1 yr)                                                              147 (19.0)   135 (16.4)   154 (19.8)   129 (20.0)   151 (19.5)   127 (17.6)    128 (17.1)    144 (17.0)   140 (17.2)     131 (18.4)   135 (18.6)   112 (17.1)   0.667
   Denosumab (1 yr)                                                                   ≤5           7 (0.9)      ≤5           6 (0.9)      10 (1.3)     ≤5            6 (0.8)       9 (1.1)      13 (1.6)       14 (2.0)     11 (1.5)     12 (1.8)     0.075
   Glucocorticoid (1 yr)                                                              74 (9.6)     68 (8.3)     79 (10.2)    55 (8.5)     69 (8.9)     68 (9.4)      54 (7.2)      63 (7.4)     68 (8.3)       65 (9.1)     64 (8.8)     65 (9.9)     0.650
  PPI                                                                                 270 (34.9)   287 (34.9)   255 (32.8)   211 (32.8)   260 (33.6)   228 (31.6)    231 (30.8)    275 (32.5)   222 (27.2)     234 (32.9)   237 (32.7)   217 (33.2)   0.128
   Anticonvulsant                                                                     ≤5           ≤5           7 (0.9)      ≤5           ≤5           ≤5            ≤5            ≤5           ≤5             ≤5           ≤5           ≤5           0.040
   Antineoplastic                                                                     13 (1.7)     11 (1.3)     7 (0.9)      6 (0.9)      ≤5           11 (1.5)      8 (1.1)       8 (0.9)      7 (0.9)        10 (1.4)     ≤5           13 (2.0)     0.278
  *Number of Unique Drugs*                                                                                                                                                                                                                            
   Mean ± SD                                                                          8.8 ± 6.4    8.8 ± 6.3    8.3 ± 6.1    8.3 ± 5.9    8.5 ± 5.8    8.5 ± 5.9     8.3 ± 6.0     7.9 ± 5.8    7.6 ± 5.7      8.2 ± 6.2    8.3 ± 6.1    8.5 ± 6.4    0.005
   Median (IQR)                                                                       8 (4--12)    7 (4--12)    7 (4--11)    8 (4--11)    7 (5--11)    8 (4--12)     7 (4--12)     7 (4--11)    7 (3--11)      7 (4--12)    7 (4--12)    8 (4--12)    0.007
  *Health-care Visits*[d](#tfn7-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                                      
   At least one GP visit                                                              606 (78.3)   665 (80.9)   662 (85.1)   506 (78.6)   593 (76.6)   566 (78.4)    584 (78.0)    660 (78.0)   652 (80.0)     565 (79.4)   553 (76.4)   488 (74.6)   \<0.001
   Any blood test                                                                     190 (24.5)   201 (24.5)   167 (21.5)   139 (21.6)   179 (23.1)   186 (25.8)    160 (21.)     190 (22.5)   199 (24.4)     168 (23.6)   159 (22.0)   157 (24.0)   0.558
   Any specialist visit                                                               640 (82.7)   710 (86.4)   672 (86.4)   543 (84.3)   649 (83.9)   621 (86.0)    616 (82.2)    743 (87.8)   677 (83.1)     594 (83.4)   623 (86.0)   530 (81.0)   0.005
   Home-care visit                                                                    207 (26.7)   210 (25.5)   196 (25.2)   142 (22.0)   191 (24.7)   167 (23.1)    208 (27.8)    216 (25.5)   193 (23.7)     180 (25.3)   161 (22.2)   165 (25.2)   0.32

Unless indicated, data represents number (percent); cell sizes \<6 are not presented for privacy.

Unless specified, comorbidities were ascertained in the 5 years prior.

Conditions present at the time of the encounter were those coded during the hip fracture hospitalization.

Unless specified, medication use was ascertained in the 180 days prior.

Unless specified, health-care visits were ascertained in the 30 days prior.

We used Chi-squared analyses, one-way ANOVA, and Kruskal-Wallis tests to determine if there were differences in covariates across the calendar months.

CKD = chronic kidney disease; RA = rheumatoid arthritis; COPD = chronic obstructive pulmonary disease; IBD = inflammatory bowel disease; AMI = acute myocardial infarction; PPI = proton pump inhibitor; GP = general practitioner.

###### 

Characteristics of patients aged 80+ with hip fractures from September 2012 to August 2013 (N=10,096)

![](cgj-22-148t3a)

                                                                                       *Sept*       *Oct*        *Nov*        *Dec*        *Jan*        *Feb*        *Mar*        *Apr*        *May*        *Jun*        *Jul*        *Aug*        *P-value*[e](#tfn15-cgj-22-148){ref-type="table-fn"}
  ------------------------------------------------------------------------------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------------------------------------------------
  Age (mean ± SD)                                                                      86.8 ± 4.8   86.4± 4.6    86.7 ± 4.7   86.6 ± 4.6   86.6 ± 4.9   86.5 ± 4.7   86.5 ± 4.7   86.3 ± 4.5   86.4 ± 4.6   86.5 ± 4.8   86.8 ± 4.8   86.9 ± 4.9   0.214
  Female                                                                               637 (75.0)   644 (70.5)   605 (73.5)   612 (71.1)   610 (70.0)   558 (73.7)   574 (74.0)   592 (70.6)   660 (72.4)   591 (71.8)   609 (72.1)   618 (74.8)   0.231
  *Income Quintile*                                                                                                                                                                                                                                
   1 (lowest)                                                                          167 (19.7)   184 (20.1)   168 (20.4)   162 (18.8)   195 (22.4)   140 (18.5)   159 (20.5)   169 (20.2)   183 (20.1)   172 (20.9)   179 (21.2)   173 (20.9)   0.631
   2                                                                                   164 (19.3)   211 (23.1)   180 (21.9)   177 (20.6)   168 (19.3)   138 (18.2)   139 (17.9)   175 (20.9)   191 (20.9)   168 (20.4)   150 (17.8)   175 (21.2)   
   3 or missing                                                                        172 (20.3)   154 (16.8)   167 (20.3)   178 (20.7)   184 (21.1)   160 (21.1)   157 (20.2)   166 (19.8)   187 (20.5)   173 (21.0)   173 (20.5)   160 (19.4)   
   4                                                                                   162 (19.1)   178 (19.5)   145 (17.6)   193 (22.4)   164 (18.8)   164 (21.7)   165 (21.3)   159 (19.0)   168 (18.4)   163 (19.8)   174 (20.6)   165 (20.0)   
   5 (highest)                                                                         184 (21.7)   187 (20.5)   163 (19.8)   151 (17.5)   161 (18.5)   155 (20.5)   156 (20.1)   169 (20.2)   183 (20.1)   147 (17.9)   169 (20.0)   153 (18.5)   
  *Residence*                                                                                                                                                                                                                                      
   Long-term care                                                                      151 (17.8)   139 (15.2)   123 (14.9)   150 (17.4)   148 (17.0)   122 (16.1)   119 (15.3)   121 (14.4)   148 (16.2)   130 (15.8)   141 (16.7)   155 (18.8)   0.397
   Missing                                                                             16 (1.9)     21 (2.3)     16 (1.9)     11 (1.3)     21 (2.4)     19 (2.5)     12 (1.5)     16 (1.9)     10 (1.1)     21 (2.6)     18 (2.1)     11 (1.3)     
  *Discharge Disposition*                                                                                                                                                                                                                          
   Acute care                                                                          81 (9.5)     77 (8.4)     80 (9.7)     89 (10.3)    78 (8.9)     73 (9.6)     69 (8.9)     74 (8.8)     80 (8.8)     75 (9.1)     91 (10.8)    94 (11.4)    0.196
   Home without support                                                                65 (7.7)     60 (6.6)     62 (7.5)     54 (6.3)     60 (6.9)     50 (6.6)     44 (5.7)     67 (8.0)     55 (6.0)     45 (5.5)     54 (6.4)     48 (5.8)     
   Home with support                                                                   145 (17.1)   176 (19.3)   168 (20.4)   155 (18.0)   168 (19.3)   128 (16.9)   141 (18.2)   191 (22.8)   187 (20.5)   169 (20.5)   177 (20.9)   144 (17.4)   
   Long-term care                                                                      250 (29.4)   247 (27.0)   210 (25.5)   246 (28.6)   232 (26.6)   231 (30.5)   232 (29.9)   235 (28.0)   268 (29.4)   249 (30.3)   252 (29.8)   238 (28.8)   
   Rehab or other ambulatory facility or missing                                       308 (36.3)   354 (38.7)   303 (36.8)   317 (36.8)   334 (38.3)   275 (36.3)   290 (37.4)   271 (32.3)   322 (35.3)   285 (34.6)   271 (32.1)   302 (36.6)   
  *Comorbidities*[a](#tfn11-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                                       
   Fall in 1 yr. prior                                                                 83 (9.8)     87 (9.5)     64 (7.8)     74 (8.6)     61 (7.0)     44 (5.8)     49 (6.3)     53 (6.3)     56 (6.1)     49 (6.0)     55 (6.5)     59 (7.1)     0.005
   Fracture in 1 yr. prior                                                             80 (9.4)     88 (9.6)     70 (8.5)     63 (7.3)     61 (7.0)     42 (5.5)     44 (5.7)     54 (6.4)     43 (4.7)     47 (5.7)     46 (5.4)     45 (5.4)     \<0.001
   Chronic liver disease                                                               19 (2.2)     18 (2.0)     22 (2.7)     30 (3.5)     18 (2.1)     14 (1.8)     23 (3.0)     19 (2.3)     22 (2.4)     23 (2.8)     19 (2.2)     26 (3.1)     0.565
   Dementia                                                                            361 (42.5)   370 (40.5)   328 (39.9)   382 (44.4)   360 (41.3)   320 (42.3)   334 (43.0)   331 (39.5)   370 (40.6)   313 (38.0)   344 (40.7)   358 (43.3)   0.322
   CKD                                                                                 124 (14.6)   122 (13.3)   111 (13.5)   140 (16.3)   129 (14.8)   131 (17.3)   115 (14.8)   120 (14.3)   120 (13.2)   115 (14.0)   119 (14.1)   134 (16.2)   0.359
   RA                                                                                  29 (3.4)     34 (3.7)     30 (3.6)     29 (3.4)     35 (4.0)     36 (4.8)     24 (3.1)     34 (4.1)     42 (4.6)     44 (5.3)     24 (2.8)     37 (4.5)     0.28
   COPD                                                                                247 (29.1)   306 (33.5)   254 (30.9)   267 (31.0)   266 (30.5)   239 (31.6)   235 (30.3)   271 (32.3)   275 (30.2)   249 (30.3)   267 (31.6)   241 (29.2)   0.794
   IBD                                                                                 ≤5           ≤5           9 (1.1)      7 (0.8)      ≤5           ≤5           8 (1.0)      ≤5           7 (0.8)      ≤5           ≤5           ≤5           0.356
   Diabetes                                                                            239 (28.2)   253 (27.7)   218 (26.5)   260 (30.2)   236 (27.1)   223 (29.5)   221 (28.5)   228 (27.2)   259 (28.4)   246 (29.9)   251 (29.7)   245 (29.7)   0.796
   Major cancer                                                                        140 (16.5)   142 (15.5)   127 (15.4)   134 (15.6)   138 (15.8)   109 (14.4)   111 (14.3)   123 (14.7)   131 (14.4)   96 (11.7)    117 (13.8)   105 (12.7)   0.245
   Alcoholism                                                                          7 (0.8)      19 (2.1)     13 (1.6)     8 (0.9)      8 (0.9)      ≤5           11           ≤5           ≤5           9 (1.1)      14 (1.7)     8 (1.0)      0.021
   Seizure                                                                             8 (0.9)      9 (1.0)      12 (1.5)     13 (1.5)     6 (0.7)      15 (2.0)     7 (0.9)      9 (1.1)      14 (1.5)     11 (1.3)     13 (1.5)     13 (1.6)     0.537
  *Other Conditions at Time of Encounter*[b](#tfn12-cgj-22-148){ref-type="table-fn"}                                                                                                                                                               
   Acute kidney injury                                                                 24 (2.8)     38 (4.2)     29 (3.5)     28 (3.3)     26 (3.0)     30 (4.0)     25 (3.2)     31 (3.7)     34 (3.7)     34 (4.1)     25 (3.0)     28 (3.4)     0.886
   Sepsis                                                                              7 (0.8)      ≤5           ≤5           11 (1.3)     ≤5           ≤5           6 (0.8)      ≤5           6 (0.7)      ≤5           8 (0.9)      ≤5           0.335
   Rhabdomyolysis                                                                      ≤5           6 (0.7)      7 (0.9)      ≤5           12 (1.4)     ≤5           6 (0.8)      ≤5           12 (1.3)     8 (1.0)      9 (1.1)      14 (1.7)     0.054
   AMI                                                                                 36 (4.2)     40 (4.4)     25 (3.0)     31 (3.6)     30 (3.4)     34 (4.5)     26 (3.4)     27 (3.2)     29 (3.2)     28 (3.4)     28 (3.3)     20 (2.4)     0.56
  *Charlson Comorbidity Index*                                                                                                                                                                                                                     
   Mean ± SD                                                                           1.5 ± 1.8    1.4 ± 1.7    1.7 ± 1.8    1.5 ± 1.9    1.4 ± 1.8    1.5 ± 1.7    1.4 ± 1.9    1.5 ± 1.8    1.3 ± 1.7    1.5 ± 1.8    1.5± 1.8     1.4 ± 1.7    0.586
   Median (IQR)                                                                        1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     1 (0--2)     0.246
   0 (no hospitalization)                                                              314 (37.0)   356 (38.9)   328 (39.9)   322 (37.4)   354 (40.6)   274 (36.2)   324 (41.8)   331 (39.5)   389 (42.7)   297 (36.1)   332 (39.3)   321 (38.9)   0.186
   1                                                                                   234 (27.6)   245 (26.8)   223 (27.1)   232 (26.9)   228 (26.1)   199 (26.3)   183 (23.6)   200 (23.9)   225 (24.7)   235 (28.6)   192 (22.7)   204 (24.7)   
   2                                                                                   105 (12.4)   130 (14.2)   116 (14.1)   119 (13.8)   126 (14.4)   126 (16.6)   114 (14.7)   125 (14.9)   123 (13.5)   123 (14.9)   143 (16.9)   133 (16.1)   
   3+                                                                                  196 (23.1)   183 (20.0)   156 (19.0)   188 (21.8)   164 (18.8)   158 (20.9)   155 (20.0)   182 (21.7)   175 (19.2)   168 (20.4)   178 (21.1)   168 (20.3)   
  *Medications*[c](#tfn13-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                                         
  Statins                                                                              347 (40.9)   366 (40.0)   302 (36.7)   346 (40.2)   350 (40.1)   346 (45.7)   304 (39.2)   350 (41.8)   352 (38.6)   345 (41.9)   354 (41.9)   340 (41.2)   0.091
  Bisphosphonate (1 yr)                                                                232 (27.3)   244 (26.7)   239 (29.0)   234 (27.2)   234 (26.8)   200 (26.4)   219 (28.2)   222 (26.5)   238 (26.1)   205 (24.9)   195 (23.1)   202 (24.5)   0.331
  Denosumab (1 yr)                                                                     12 (1.4)     13 (1.4)     10 (1.2)     12 (1.4)     19 (2.2)     19 (2.5)     12 (1.5)     17 (2.0)     18 (2.0)     20 (2.4)     22 (2.6)     27 (3.3)     0.072
  Glucocorticoid (1 yr)                                                                60 (7.1)     69 (7.5)     62 (7.5)     73 (8.5)     74 (8.5)     56 (7.4)     46 (5.9)     69 (8.2)     60 (6.6)     76 (9.2)     58 (6.9)     53 (6.4)     0.316
  PPI                                                                                  319 (37.6)   333 (36.4)   291 (35.4)   300 (34.8)   305 (35.0)   266 (35.1)   281 (36.2)   303 (36.2)   322 (35.3)   294 (35.7)   315 (37.3)   312 (37.8)   0.963
  Anticonvulsant                                                                       ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           ≤5           0.243
  Antineoplastic                                                                       13 (1.5)     23 (2.5)     20 (2.4)     11 (1.3)     19 (2.2)     8 (1.1)      19 (2.4)     9 (1.1)      12 (1.3)     7 (0.9)      12 (1.4)     9 (1.1)      0.023
  *Number of Unique Drugs*                                                                                                                                                                                                                         
   Mean ± SD                                                                           10.2 ± 6.1   9.8 ± 6.0    9.6 ± 6.2    10.3 ± 6.2   10.0 ± 6.3   10.0 ± 6.5   10.0 ± 6.4   10.2 ± 6.3   9.9 ± 6.2    10.1 ± 6.5   10.0 ± 6.3   10.3 ± 6.4   0.442
   Median (IQR)                                                                        9 (6--14)    9(5--13)     9(5--13)     9 (6--14)    9 (5--14)    9 (5--13)    9 (5--14)    10 (6--14)   9 (5--14)    9 (5--14)    9 (5--14)    10 (6--14)   0.307
  *Health-care Visits*[d](#tfn14-cgj-22-148){ref-type="table-fn"}                                                                                                                                                                                  
   At least one GP visit                                                               640 (75.4)   725 (79.3)   678 (82.4)   673 (78.2)   666 (76.4)   561 (74.1)   583 (75.1)   633 (75.5)   676 (74.1)   620 (75.3)   653 (77.3)   594 (71.9)   \<0.001
   Any blood test                                                                      257 (30.3)   276 (30.2)   253 (30.7)   270 (31.4)   227 (26.0)   228 (30.1)   218 (28.1)   231 (27.6)   283 (31.0)   240 (29.2)   247 (29.2)   227 (27.5)   0.329
   Any specialist visit                                                                694 (81.7)   745 (81.5)   682 (82.9)   702 (81.5)   697 (79.9)   616 (81.4)   637 (82.1)   715 (85.3)   734 (80.5)   681 (82.7)   702 (83.1)   669 (81.0)   0.316
   Home care visit                                                                     263 (31.0)   278 (30.4)   253 (30.7)   291 (33.8)   280 (32.1)   239 (31.6)   264 (34.0)   261 (31.1)   297 (32.6)   260 (31.6)   267 (31.6)   258 (31.2)   0.906

Unless indicated, data represents number (percent); cell sizes \<6 are not presented for privacy.

Unless specified, comorbidities were ascertained in the 5 years prior.

Conditions present at the time of the encounter were those coded during the hip fracture hospitalization

Unless specified, medication use was ascertained in the 180 days prior.

Unless specified, healthcare utilization was ascertained in the 30 days prior.

We used Chi-squared analyses, one-way ANOVA, and Kruskal-Wallis tests to determine if there were differences in covariates across the calendar months.

CKD = chronic kidney disease; RA = rheumatoid arthritis; COPD = chronic obstructive pulmonary disease; IBD = inflammatory bowel disease; AMI = acute myocardial infarction; PPI = proton pump inhibitor; GP = general practitioner.
